Structure of Human Enterovirus 70 and Its Inhibition by Capsid-Binding Compounds.

J Virol

Structural Virology, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.

Published: September 2022

Enterovirus 70 (EV70) is a human pathogen belonging to the family . EV70 is transmitted by eye secretions and causes acute hemorrhagic conjunctivitis, a serious eye disease. Despite the severity of the disease caused by EV70, its structure is unknown. Here, we present the structures of the EV70 virion, altered particle, and empty capsid determined by cryo-electron microscopy. The capsid of EV70 is composed of the subunits VP1, VP2, VP3, and VP4. The partially collapsed hydrophobic pocket located in VP1 of the EV70 virion is not occupied by a pocket factor, which is commonly present in other enteroviruses. Nevertheless, we show that the pocket can be targeted by the antiviral compounds WIN51711 and pleconaril, which block virus infection. The inhibitors prevent genome release by stabilizing EV70 particles. Knowledge of the structures of complexes of EV70 with inhibitors will enable the development of capsid-binding therapeutics against this virus. Globally distributed enterovirus 70 (EV70) causes local outbreaks of acute hemorrhagic conjunctivitis. The discharge from infected eyes enables the high-efficiency transmission of EV70 in overcrowded areas with low hygienic standards. Currently, only symptomatic treatments are available. We determined the structures of EV70 in its native form, the genome release intermediate, and the empty capsid resulting from genome release. Furthermore, we elucidated the structures of EV70 in complex with two inhibitors that block virus infection, and we describe the mechanism of their binding to the virus capsid. These results enable the development of therapeutics against EV70.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472761PMC
http://dx.doi.org/10.1128/jvi.00604-22DOI Listing

Publication Analysis

Top Keywords

ev70
13
structures ev70
12
genome release
12
enterovirus ev70
8
acute hemorrhagic
8
hemorrhagic conjunctivitis
8
ev70 virion
8
empty capsid
8
block virus
8
virus infection
8

Similar Publications

Introduction: Viral infections are the predominant cause of acute hemorrhagic conjunctivitis (AHC) across the globe. From July to August of 2023, a large-scale conjunctivitis outbreak was witnessed in India, affecting a large number of individuals. The present study was initiated to identify the causative agent responsible for the AHC outbreak in Kalburgi district of Karnataka state.

View Article and Find Full Text PDF

Emerging Therapeutics in the Fight Against EV-D68: A Review of Current Strategies.

Influenza Other Respir Viruses

December 2024

Infection and Immunity Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Malaysia.

Enterovirus-D68 (EV-D68) was first identified in 1962 in pediatric patients with acute respiratory conditions in California, USA (US). From the 1970s to 2005, EV-D68 was underestimated due to limited data and serotyping methods. In 2014, the United States experienced outbreaks of acute flaccid myelitis (AFM) in children EV-D68 positive.

View Article and Find Full Text PDF

Discovery of A-967079 as an Enterovirus D68 Antiviral by Targeting the Viral 2C Protein.

ACS Infect Dis

December 2024

Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.

Enterovirus D68 (EV-D68) has had several outbreaks worldwide, yet no FDA-approved antiviral is available for treating this viral infection. EV-D68 infection typically leads to respiratory illnesses and, in severe cases, can cause neurological complications and even death, particularly in children. This study identified a small molecule, A-967079, as an EV-D68 antiviral through phenotypical screening.

View Article and Find Full Text PDF

Some assembly required: a single-RNA vaccine against enterovirus-D68.

Trends Pharmacol Sci

December 2024

Department of Microbiology and Immunology and Center for Pathogen Research, University of Maryland School of Medicine, 685 W. Baltimore Avenue, Baltimore, MD 21201, USA. Electronic address:

A single-RNA-based vaccine against enterovirus-D68, a respiratory virus and causative agent of severe paralytic disease in children, by the Erasmus group shows great promise in generating broadly cross-neutralizing antibodies in mice and macaque models of infection.

View Article and Find Full Text PDF

A Novel Peptide from VP1 of EV-D68 Exhibits Broad-Spectrum Antiviral Activity Against Human Enteroviruses.

Biomolecules

October 2024

National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

Article Synopsis
  • Enteroviruses, including polioviruses and non-polio variants, are a significant health concern, with over 116 types affecting humans annually.
  • A novel peptide called P25 from EV-D68 shows broad antiviral activity against multiple enterovirus species by targeting key viral structures and functions.
  • P25 has the potential to serve as a universal anti-enterovirus drug candidate due to its ability to block viral receptor binding, inhibit viral genome release, and reduce the production of infectious viral particles.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!